Interferon (IFN)-α is able to stimulate many cellular genes and inhibit the replication of various viruses. However, it is unknown whether some IFN-stimulated genes (ISGs) specifically inhibit hepatitis B virus (HBV) replication. Therefore, we attempted to identify ISGs with antiviral activities against HBV. Knockdown of IFN-induced proteins with tetratricopeptide repeats 1 and 2 (IFIT1 and IFIT2) in HepG2.2.15 led to markedly increased HBV replication. Consistently, this effect was verified by transient transfection with a replication-competent HBV clone in HepG2 and Huh7. However, IFN-α stimulation could override the knockdown by siRNAs and enhance the expression of IFIT1 and IFIT2, leading to reduced HBV replication. Silencing of IFIT1 or IFIT2 decreased the expression of the corresponding genes while other ISGs like MxA were not affected. Northern blot analysis showed that IFIT1 and IFIT2 knockdown slightly increased the levels of HBV 3.5, 2.4 and 2.1 kb transcripts, while IFIT1 and IFIT2 overexpression did not change their levels. Consistently, the reporter assays with HBV promoters demonstrated that IFIT1 and IFIT2 differentially but only modestly regulated HBV promoter activity. Thus, IFIT1 and IFIT2 contribute significantly to the regulation of HBV replication, likely at both transcriptional and posttranscriptional steps.

Keywords:
IFIT1, IFIT2, HBV
1.
Seeger C, Mason WS: Hepatitis B virus biology. Microbiol Mol Biol Rev 2000;64:51-68.
2.
McMahon BJ: Epidemiology and natural history of hepatitis B. Semin Liver Dis 2005;25(suppl 1):3-8.
3.
Guidotti LG, Ando K, Hobbs MV, Ishikawa T, Runkel L, Schreiber RD, Chisari FV: Cytotoxic t lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice. Proc Natl Acad Sci USA 1994;91:3764-3768.
4.
Guidotti LG, Ishikawa T, Hobbs MV, Matzke B, Schreiber R, Chisari FV: Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 1996;4:25-36.
5.
Guidotti LG, Rochford R, Chung J, Shapiro M, Purcell R, Chisari FV: Viral clearance without destruction of infected cells during acute HBV infection. Science 1999;284:825-829.
6.
Wieland S, Thimme R, Purcell RH, Chisari FV: Genomic analysis of the host response to hepatitis B virus infection. Proc Natl Acad Sci USA 2004;101:6669-6674.
7.
Wieland SF, Chisari FV: Stealth and cunning: hepatitis B and hepatitis C viruses. J Virol 2005;79:9369-9380.
8.
Dunn C, Peppa D, Khanna P, Nebbia G, Jones M, Brendish N, Lascar RM, Brown D, Gilson RJ, Tedder RJ, Dusheiko GM, Jacobs M, Klenerman P, Maini MK: Temporal analysis of early immune responses in patients with acute hepatitis B virus infection. Gastroenterology 2009;137:1289-1300.
9.
Guidotti LG, Borrow P, Hobbs MV, Matzke B, Gresser I, Oldstone MB, Chisari FV: Viral cross talk: intracellular inactivation of the hepatitis B virus during an unrelated viral infection of the liver. Proc Natl Acad Sci USA 1996;93:4589-4594.
10.
Wieland SF, Guidotti LG, Chisari FV: Intrahepatic induction of alpha/beta interferon eliminates viral RNA-containing capsids in hepatitis B virus transgenic mice. J Virol 2000;74:4165-4173.
11.
Wieland SF, Eustaquio A, Whitten-Bauer C, Boyd B, Chisari FV: Interferon prevents formation of replication-competent hepatitis B virus RNA-containing nucleocapsids. Proc Natl Acad Sci USA 2005;102:9913-9917.
12.
Xu C, Guo H, Pan XB, Mao R, Yu W, Xu X, Wei L, Chang J, Block TM, Guo JT: Interferons accelerate decay of replication-competent nucleocapsids of hepatitis B virus. J Virol 2010;84:9332-9340.
13.
Anderson AL, Banks KE, Pontoglio M, Yaniv M, McLachlan A: Alpha/beta interferon differentially modulates the clearance of cytoplasmic encapsidated replication intermediates and nuclear covalently closed circular hepatitis B virus (HBV) DNA from the livers of hepatocyte nuclear factor 1α-null HBV transgenic mice. J Virol 2005;79:11045-11052.
14.
Wieland SF, Vega RG, Muller R, Evans CF, Hilbush B, Guidotti LG, Sutcliffe JG, Schultz PG, Chisari FV: Searching for interferon-induced genes that inhibit hepatitis B virus replication in transgenic mouse hepatocytes. J Virol 2003;77:1227-1236.
15.
Nguyen DH, Hu J: Reverse transcriptase- and RNA packaging signal-dependent incorporation of APOBEC3G into hepatitis B virus nucleocapsids. J Virol 2008;82:6852-6861.
16.
Baumert TF, Rosler C, Malim MH, von Weizsacker F: Hepatitis B virus DNA is subject to extensive editing by the human deaminase APOBEC3C. Hepatology 2007;46:682-689.
17.
Suspene R, Guetard D, Henry M, Sommer P, Wain-Hobson S, Vartanian JP: Extensive editing of both hepatitis B virus DNA strands by APOBEC3 cytidine deaminases in vitro and in vivo. Proc Natl Acad Sci USA 2005;102:8321-8326.
18.
Gordien E, Rosmorduc O, Peltekian C, Garreau F, Brechot C, Kremsdorf D: Inhibition of hepatitis B virus replication by the interferon-inducible MxA protein. J Virol 2001;75:2684-2691.
19.
Peltekian C, Gordien E, Garreau F, Meas-Yedid V, Soussan P, Willams V, Chaix ML, Olivo-Marin JC, Brechot C, Kremsdorf D: Human MxA protein participates to the interferon-related inhibition of hepatitis B virus replication in female transgenic mice. J Hepatol 2005;43:965-972.
20.
Li N, Zhang L, Chen L, Feng W, Xu Y, Chen F, Liu X, Chen Z, Liu W: MxA inhibits hepatitis B virus replication by interaction with hepatitis B core antigen. Hepatology 2012;56:803-811.
21.
Gao B, Duan Z, Xu W, Xiong S: Tripartite motif-containing 22 inhibits the activity of hepatitis B virus core promoter, which is dependent on nuclear-located ring domain. Hepatology 2009;50:424-433.
22.
Mao R, Zhang J, Jiang D, Cai D, Levy JM, Cuconati A, Block TM, Guo JT, Guo H: Indoleamine 2,3-dioxygenase mediates the antiviral effect of gamma interferon against hepatitis B virus in human hepatocyte-derived cells. J Virol 2011;85:1048-1057.
23.
Wacher C, Muller M, Hofer MJ, Getts DR, Zabaras R, Ousman SS, Terenzi F, Sen GC, King NJ, Campbell IL: Coordinated regulation and widespread cellular expression of interferon-stimulated genes (ISG) ISG-49, ISG-54, and ISG-56 in the central nervous system after infection with distinct viruses. J Virol 2007;81:860-871.
24.
Terenzi F, Hui DJ, Merrick WC, Sen GC: Distinct induction patterns and functions of two closely related interferon-inducible human genes, ISG54 and ISG56. J Biol Chem 2006;281:34064-34071.
25.
Guo J, Hui DJ, Merrick WC, Sen GC: A new pathway of translational regulation mediated by eukaryotic initiation factor 3. EMBO J 2000;19:6891-6899.
26.
Hui DJ, Bhasker CR, Merrick WC, Sen GC: Viral stress-inducible protein p56 inhibits translation by blocking the interaction of eIF3 with the ternary complex eIF2.GTP.MET- tRNAi. J Biol Chem 2003;278:39477-39482.
27.
Li HT, Su YP, Cheng TM, Xu JM, Liao J, Chen JC, Ji CY, Ai GP, Wang JP: The interaction between interferon-induced protein with tetratricopeptide repeats-1 and eukaryotic elongation factor-1A. Mol Cell Biochem 2010;337:101-110.
28.
Pichlmair A, Lassnig C, Eberle CA, Gorna MW, Baumann CL, Burkard TR, Burckstummer T, Stefanovic A, Krieger S, Bennett KL, Rulicke T, Weber F, Colinge J, Muller M, Superti-Furga G: IFIT1 is an antiviral protein that recognizes 5′-triphosphate RNA. Nat Immunol 2011;12:624-630.
29.
Wang C, Pflugheber J, Sumpter R Jr, Sodora DL, Hui D, Sen GC, Gale M Jr: Alpha interferon induces distinct translational control programs to suppress hepatitis C virus RNA replication. J Virol 2003;77:3898-3912.
30.
Terenzi F, Saikia P, Sen GC: Interferon-inducible protein, p56, inhibits HPV DNA replication by binding to the viral protein E1. EMBO J 2008;27:3311-3321.
31.
Daffis S, Szretter KJ, Schriewer J, Li J, Youn S, Errett J, Lin TY, Schneller S, Zust R, Dong H, Thiel V, Sen GC, Fensterl V, Klimstra WB, Pierson TC, Buller RM, Gale M Jr, Shi PY, Diamond MS: 2′-O methylation of the viral mRNA cap evades host restriction by IFIT family members. Nature 2010;468:452-456.
32.
Zhang X, Ma Z, Liu H, Liu J, Meng Z, Broering R, Yang D, Schlaak JF, Roggendorf M, Lu M: Role of Toll-like receptor 2 in the immune response against hepadnaviral infection. J Hepatol 2012;57:522-528.
33.
Qiu J, Qin B, Rayner S, Wu CC, Pei RJ, Xu S, Wang Y, Chen XW: Novel evidence suggests hepatitis B virus surface proteins participate in regulation of HBV genome replication. Virol Sin 2011;26:131-138.
34.
Zhang X, Zhang E, Ma Z, Pei R, Jiang M, Schlaak JF, Roggendorf M, Lu M: Modulation of hepatitis B virus replication and hepatocyte differentiation by microRNA-1. Hepatology 2011;53:1476-1485.
35.
Mao R, Zhang J, Jiang D, Cai D, Levy JM, Cuconati A, Block TM, Guo JT, Guo H: Indoleamine 2,3-dioxygenase mediates the antiviral effect of gamma interferon against hepatitis B virus in human hepatocyte-derived cells. J Virol 2012;85:1048-1057.
36.
Guidotti LG, Morris A, Mendez H, Koch R, Silverman RH, Williams BR, Chisari FV: Interferon-regulated pathways that control hepatitis B virus replication in transgenic mice. J Virol 2002;76:2617-2621.
37.
Hosel M, Quasdorff M, Wiegmann K, Webb D, Zedler U, Broxtermann M, Tedjokusumo R, Esser K, Arzberger S, Kirschning CJ, Langenkamp A, Falk C, Buning H, Rose-John S, Protzer U: Not interferon, but interleukin-6 controls early gene expression in hepatitis B virus infection. Hepatology 2009;50:1773-1782.
38.
Lucifora J, Durantel D, Testoni B, Hantz O, Levrero M, Zoulim F: Control of hepatitis B virus replication by innate response of HepaRG cells. Hepatology 2010;51:63-72.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.